AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
SAN FRANCISCO--Another J.P. Morgan Healthcare Conference is in the books, and biopharma's movers, shakers and up-and-comers have headed back to Boston, Basel and Bangalore. This year, in the shadow of the best market for biotech IPOs since 2000, there's fresh optimism that capital will continue to flow into drug developers' pockets, whether via more market debuts or through the many top-tier VCs putting together new funds.
To no one's surprise, cancer immunotherapies are hogging much of the spotlight, but Intercept's explosive week put NASH near the top of the list of biopharma buzzwords, and a host of promising RNA therapies from companies big and small grabbed some headlines. Through it all, the Fierce team was darting in and out of presentations, one-on-ones and cafe chats in and around Union Square to bring you this, our annual industry barometer.
POPULAR COMMENT THREADS
Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.
CRO Theorem Clinical Research has expanded its partnership with eClinical provider Medidata, tapping technology that will allow it to capture data directly from patients.
Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.
Global CRO Quintiles is reaching out to software provider OmniComm to replace its Phase I eClinical technology, signing a 5-year deal with the Florida company.
Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.
CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.
From Our Sister Sites
Lombard Medical revived plans to go public with a revised stateside IPO. The news comes less than two weeks after the company decided to postpone its public offering, citing poor market conditions.
France's bioMérieux reported a rise in quarterly earnings of 3.3%, compared to the first three months of 2013, to $512.50 million.